The largest database of trusted experimental protocols

17 protocols using agilent sureselect target enrichment kit

1

Targeted Cancer Sequencing Using FFPE Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols
Targeted sequencing of 170 cancer-related gene panels was performed using formalin-fixed, paraffin-embedded tissue (FFPE) samples as previously described [13 (link)]. All FFPE materials had a short cold ischemic time not exceeding 2 hours, fixation time ranging from 8 to 72 hours, and were aged between 0 and 9 years.
In brief, approximately 3 µg of genomic DNA was extracted from FFPE tumor tissues, and the sequencing library was prepared using an Agilent SureSelect Target Enrichment Kit (Agilent Technologies, Santa Clara, CA, USA) following the manufacturer’s guidelines. High-throughput sequencing was performed using the HiSeq 2500 system (Illumina, San Diego, CA, USA) (Macrogen Inc., Seoul, Korea). After quality control of the FASTQ files, sequencing reads were aligned to the reference genome (GRCh37/hg19) using Burrows-Wheeler Aligner-MEM (BWA-MEM) [14 ]. Single nucleotide variants and small insertions and deletions (INDELs) were detected using the MuTect2 algorithm [15 (link)]. SnpEff and SnpSift v4.3i [16 (link)] with dbNSFP v2.9.3 [17 (link)] were used for variant annotation with various databases including the OncoKB [18 ] and ClinVar archives [19 (link)].
+ Open protocol
+ Expand
2

Comprehensive Tumor Genomic Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Formalin‐fixed, paraffin‐embedded tumor tissues, and blood samples were prepared using the Agilent SureSelect Target Enrichment Kit (Agilent Technologies, Inc.). Targeted deep sequencing data were generated using Illumina NovaSeq 6000 (Illumina) with a read length of 101 bp and a mean depth of target regions of 1,000X. Read alignment and somatic mutation calling were performed using the DNA Pipeline of the Illumina DRAGEN Bio‐IT Platform v3.6 (Illumina). Tumor somatic mutation annotation was performed using Oncotator v1.9.9.0. Somatic copy number alterations (SCNA) were called using CNVkit v0.9.5. A combined somatic mutation and SCNA oncoplot was drawn using ComplexHeatmap v2.4.3. Copy number alterations were defined as copy number amplifications (copy number >5) and copy number deletions (copy number = 1 or 0).
+ Open protocol
+ Expand
3

High-Throughput Panel Sequencing of Eye Diseases

Check if the same lab product or an alternative is used in the 5 most similar protocols
Panel‐based next‐generation sequencing was accomplished on all subjects recruited in this study. We designed a high‐throughput chip that contains 792 eye‐diseases‐related genes (Supplementary Table S1) to actualize precise targeted sequencing. The Agilent SureSelect Target Enrichment Kit (Agilent Technologies, Inc., USA) was utilized to conduct DNA libraries and then the reads were sequenced on MGISEQ‐2000 platform (DNBSEQ‐G400) (Gao et al., 2019 (link); Li et al., 2021 (link)). The size of the generated reads during paired‐end sequencing was 100 bp and the average depth was 704X while the median depth was 677X.
+ Open protocol
+ Expand
4

Whole Exome Sequencing of PA Cases

Check if the same lab product or an alternative is used in the 5 most similar protocols
Genomic DNA samples of the PA cases and healthy controls were obtained with written informed consent. DNA extraction from blood samples was carried out using the QIAamp™ DNA and Blood Mini kit (Qiagen) according to the manufacturer's instructions. WES was performed using the Agilent Sure Select Target Enrichment kit (V6 58 Mb; Agilent Technologies) for sequence capture and the Illumina HiSeq2500 for sequencing (Illumina) to a target depth of 100×.
+ Open protocol
+ Expand
5

Targeted NGS for Prognostic Modeling

Check if the same lab product or an alternative is used in the 5 most similar protocols
For 375 of the 576 patients complete clinical information as well as genetic information from a 36-gene panel targeted next-generation sequencing assay were available for prognostic modeling. The regions of these 36 genes were selected for custom target capture using Agilent SureSelect Target Enrichment Kit (Agilent Technologies, Santa Clara, United States). Libraries derived from each DNA sample were prepared using NEB Ultra II (New England Biolabs, Ipswitch, United States) and individually barcoded by dual indexing. Sequencing was performed on an HiSeq 4000 (Illumina) with 150 bp paired-end reads. Forty-eight pooled libraries per lane were sequenced to a median read depth of ~400x. The custom panel of target regions covered all coding regions and consensus splice sites from the following 36 genes: ASXL1, CALR, CBL, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, IKZF1, JAK2, KRAS, MPL, NPM1, NRAS, PHF6, PTPN11, RUNX1, SETBP1, SF3B1, SH2B3, SRSF2, TET2, TP53, U2AF1, and ZRSR2. Paired-end reads were processed and analyzed as previously described8 (link).
+ Open protocol
+ Expand
6

Whole Exome Sequencing of Blood DNA

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood DNA was extracted using the QIAampTM DNA and Blood Mini Kit (Qiagen, Germany) following the standard instructions. The DNA concentration and quality were assessed by measuring the 260/280 optical density value on a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, USA). WES was performed using the Agilent Sure Select Target Enrichment kit (V6 58 Mbp; Agilent Technologies, USA) for sequence capture and Illumina HiSeq2500 for sequencing (Illumina, USA).
+ Open protocol
+ Expand
7

Whole Exome Sequencing and CNV Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood samples were obtained and DNA was extracted using the QIAamp DNA Blood Midi Kit (Qiagen, Germany). WES samples were captured with the Agilent Sure Select Target Enrichment kit (V6 58 Mb; Agilent Technologies, United States) and sequenced on the Illumina HiSeq 2500 platform (Glessner et al., 2014 (link); Li et al., 2015 (link)). CNV coordinates were converted to the GRCh37/hg19 build using the UCSC Genome Browser LiftOver tool. CNVs with 50% or larger overlap with telomere, centromere, segmental duplications, or immunoglobulin regions were excluded (Hanemaaijer et al., 2012 (link)). After filtering we screened out rare CNVs by comparing with the Database of Genomic Variants (DGV1) and Online Mendelian Inheritance in Man (OMIM2).
+ Open protocol
+ Expand
8

Targeted Exome Sequencing for Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
A total of 1μg DNA was used to generate genomic DNA libraries according to the protocols suggested by Illumina. A custom targeted capture kit was designed using Agilent Sureselect tools, covering all exons of the 83 genes (Supplementary Table 1). The total coverage of the chip was 434 kilobases. The target enrichment was performed using the Agilent SureSelect Target Enrichment kit (Agilent Technologies). The amplified DNA libraries were sequenced with the Illumina MiSeq Genome Analyzer (Illumina, San Diego, CA, USA), yielding 75 bp of paired end sequences.
Sequenced reads were then aligned to the reference human genome (GRCh37) using Burrows-Wheeler Aligner (BWA, v.0.7.10), and variant calls were generated by the Genome Analysis Toolkit (GATK, v 2.3.1). Sequencing statistics for each sample were listed in Supplementary Table 2. The coding regions of the 83 genes were selected for their association with cancer risk based on published evidences. Mutations were filtered for sequencing quality and depth of coverage.
+ Open protocol
+ Expand
9

Whole Exome Sequencing Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Whole exome sequencing was applied for sequencing in the first group. WES was carried out using the Agilent Sure Select Target Enrichment kit (V6 58 Mb; Agilent Technologies) for sequence capture and the Illumina HiSeq2500 for sequencing (Illumina) to a target depth of 100 (Chen et al., 2020 (link); Shi et al., 2020 (link); Shi et al., 2018 (link)).
+ Open protocol
+ Expand
10

LRRK2 Gene Sequencing Workflow

Check if the same lab product or an alternative is used in the 5 most similar protocols
For the discovery series, genomic DNA was extracted from peripheral blood monocytes using standard protocols. Targeted sequencing was performed by the Mayo Clinic Genome Facility. The LRRK2 gene/region (NM_198578) including introns, exons, UTRs and 10Kb upstream and downstream (165Kb) was captured using Agilent SureSelect Target Enrichment kit (Agilent Technologies, Santa Clara, CA). Samples were processed using paired-end DNA sequencing on the Illumina HighSeq 2000 platform (48 samples per lane).
For the independent replication series, whole-genome sequencing was performed by Macrogen, Inc. on whole-blood extracted DNA samples. Samples were prepared according to the Illumina TruSeq PCR Free DNA sample Preparation Guide, with a final library of 300-400 bp average insert sizes. The libraries were multiplexed and sequenced using Illumina HiSeq X Ten Sequencer. Only variants that were nominated as potential drivers of the LRRK2 GWAS association signal in analysis of the discovery series were examined in analysis of the replication series.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!